Since 2013, Delbert Pharma has been preserving the market availability of drugs considered critical to our healthcare system and repositioning some for new indications, notably in rare diseases. Our commitment, as defenders of the pharmaceutical heritage, is to maintain access to essential medications to ensure the continuity of treatments for all.

To support their European development, Laboratoires DELBERT become DELBERT Pharma in March 2024. 

This page is not intended to report adverse events that may be related to the medications marketed by Delbert Pharma. For this, please contact your healthcare professional. Delbert Pharma constantly monitors the safety of its drugs and encourages you to report any side effects directly at +33 (0) 1 46 99 68 20 or pharmacovigilance@delbert.fr.

#RevivingCriticalMedicines

Delbert Pharma

Franck Hamalian

This department ensures the quality and compliance of pharmaceutical products and processes.

Quality Assurance

This department manages compliance with regulations and oversees the approval processes for pharmaceutical products.

Regulatory Affairs

This department oversees financial strategy, planning, and management of the organization's financial resources.

Finance Leadership

This department focuses on managing and coordinating international development initiatives and communication strategies.

Delbert Pharma

Org chart

Teams

Quality Assurance

Regulatory Affairs

Finance Leadership

International Development

Offices

Delbert Pharma

Org chart

Teams

Quality Assurance

Regulatory Affairs

Finance Leadership

International Development

Offices

Related companies